STRS Ohio’s Spyre Therapeutics SYRE Stock Holding History

STRS Ohio’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Buy	11,500 +7,000	+156%	+$511K	﹤0.01%	730
2026 Q1	$227K	Buy	+4,500	New	+$170K	﹤0.01%	1445
2020 Q3	–	Sell	-192	Closed	-$44K	–	2275
2020 Q2	$44K	Hold	192	–	–	﹤0.01%	1933
2020 Q1	$22K	Hold	192	–	–	﹤0.01%	1900
2019 Q4	$36K	Hold	192	–	–	﹤0.01%	1935
2019 Q3	$36K	Hold	192	–	–	﹤0.01%	1924
2019 Q2	$32K	Hold	192	–	–	﹤0.01%	1982
2019 Q1	$38K	Hold	192	–	–	﹤0.01%	1916
2018 Q4	$35K	Hold	192	–	–	﹤0.01%	1926
2018 Q3	$45K	Hold	192	–	–	﹤0.01%	1968
2018 Q2	$50K	Buy	+192	New	+$47.2K	﹤0.01%	1975

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

STRS Ohio's SYRE Position: Q2 2026 in Review

STRS Ohio increased its Spyre Therapeutics (SYRE) stake by 156% in Q2 2026, buying an estimated $511K and bringing the position to 11,500 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #730.

STRS Ohio first reported a position in SYRE in Q2 2018 and has held it in 11 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

STRS Ohio held 11,500 shares of Spyre Therapeutics worth $1.02M as of Q2 2026.
STRS Ohio bought 7,000 Spyre Therapeutics shares in Q2 2026, an estimated $511K.
Spyre Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #730 holding.
STRS Ohio first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 11 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.